Candida Infection Biology – fungal armoury, battlefields ... - FINSysB
Candida Infection Biology – fungal armoury, battlefields ... - FINSysB
Candida Infection Biology – fungal armoury, battlefields ... - FINSysB
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Tackling the <strong>Candida</strong> spp infection spectrum with first-inclass<br />
antimicrobial peptide technology<br />
Dr Deborah A O’Neil<br />
NovaBiotics Ltd, Cruickshank Building, Aberdeen, AB21 9TR, UK<br />
Applying a biology-led, rational drug design approach, NovaBiotics has developed<br />
patented antimicrobial peptide technology from which Novamycin ® , a potently<br />
fungicidal API has been derived. Novamycin ® has a novel, membranolytic mode of<br />
action against which acquired resistance cannot develop in target <strong>fungal</strong> pathogens<br />
and is equally active against metabolically active and non-metabolising fungi.<br />
Novamycin ® is active against all <strong>Candida</strong> spp, Cryptococcus spp and limited<br />
Aspergillus spp. Novamycin ® demonstrates efficacy and is well tolerated in wellestablished,<br />
clinically relevant in vivo models of <strong>Candida</strong> spp sepsis (neutropenic<br />
and immunocompetant models), oral pharyngeal candidiasis and vaginal<br />
candidiasis. Novamycin ® will enter the clinical phase of development in the very<br />
near future for topical and mucosal indications whilst in parallel, formulation and<br />
delivery for systemic application in sepsis is further optimised. Novamycin ® offers<br />
a novel first-in-class API solution not only to the whole spectrum of <strong>Candida</strong> spp.<br />
infections, but to those caused by other clinically relevant yeasts and moulds.<br />
92
Change language